The banner on Seattle Genetics proclaims “Focused on unmet medical needs in oncology”. The company has released a number of new treatments for various cancers since January, 2016. The company is engaged in clinical trials which are posted on its website. The focus is on various lymphomas, leukemia and several solid based tumor types, among other research.
Successful new medications have been developed under the leadership of Clay Siegall. They have received recognition and approval in the United States, Canada and in Europe. Educationally Dr. Siegall‘s background includes a B.S. in Zoology from the University of Maryland. His Ph.D. in Genetics was conferred by George Washington University.
Clay Siegall, PhD. Is a trained scientist. He is giving much needed clinical attention to the development of targeted cancer therapies; Dr. Siegall shows his passion for helping patients as he leads his company in developing therapies for cancers that have received little attention. He is known for scientific innovation through meticulous research and demonstrates high standards in drug development practices.
Dr. Clay Siegall is co-founder of Seattle Genetics as well as being the Preside, CEO and Chairman of the Board of Directors of that same company. In addition he serves on the boards of directors of several other research focused biotechnology companies such as gentyx and Mirna. He is a leader in the field of research and treatment and holds fifteen patents.
Dr. Siegall’s professional history includes the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, and the National Institutes of Health prior to the founding of Seattle Genetics in 1998. Seventy publications in the medical field list him as an author.
The field of oncology is fortunate to have Clay Siegall involved in working for treatments of underserved diagnoses. His company, Seattle Genetics, does well both in research. It also offers a very profitable investment opportunity. As a leader Dr. Clay Siegall has his steady hand on the research, development and financial aspects of Seattle Genetics. It is a company that will be strong in the future, both in trading and in training and development of future research for the service of people with unmet treatment needs for their cancers.